-
公开(公告)号：US12109199B2
公开(公告)日：2024-10-08
申请号：US16967457
申请日：2019-02-06
IPC分类号： A61K31/436 , A61K9/00
CPC分类号： A61K31/436 , A61K9/0014
摘要： Methods for the treatment of cutaneous vascular conditions and cutaneous proliferative conditions are provided. The methods employ topical administration of mammalian target of rapamycin (mTOR) inhibitors such as sirolimus (rapamycin) and everolimus. Conditions treatable by the disclosed methods include venolymphatic malformations, acne, acne rosacea, periorificial dermatitis, acne vulgaris, cutaneous capillary malformation-arteriovenous malformation (CM-AVM) syndrome, RASopathies, Langerhans cell histiocytosis, non-Langerhans cell histiocytosis, scars, hypertrophic or keloidal scars, Proteus syndrome, PIK3CA-related overgrowth spectrum (PROS), PTEN hamartoma tumor syndromes, cutaneous malignancies and tumors associated with PI3K/AKT/mTOR mutations, keratodermas, acanthosis nigricans, Birt-Hogg-Dube syndrome, Brooke-Speigler syndrome, cylindromas, and epidermal nevi. Also provided are formulations and pharmaceutical compositions having mTOR inhibitor as principal therapeutically active ingredient useful in practicing the methods.
-
公开(公告)号：US12020687B2
公开(公告)日：2024-06-25
申请号：US18164782
申请日：2023-02-06
发明人： Joe Garman , Ophir Frieder
IPC分类号： G10L13/00 , G06F40/263 , G06N3/08 , G10L13/047 , G10L13/08 , G10L13/10 , G10L21/00 , G10L25/00
CPC分类号： G10L13/10 , G06F40/263 , G06N3/08 , G10L13/047 , G10L13/086
摘要： Embodiments of the present systems and methods may provide techniques for synthesizing speech in any voice in any language in any accent. For example, in an embodiment, a text-to-speech conversion system may comprise a text converter adapted to convert input text to at least one phoneme selected from a plurality of phonemes stored in memory, a machine-learning model storing voice patterns for a plurality of individuals and adapted to receive the at least one phoneme and an identity of a speaker and to generate acoustic features for each phoneme, and a decoder adapted to receive the generated acoustic features and to generate a speech signal simulating a voice of the identified speaker in a language.
-
公开(公告)号：US11869664B2
公开(公告)日：2024-01-09
申请号：US17852521
申请日：2022-06-29
发明人： Ophir Frieder , Hao-Ren Yao , Der-Chen Chang
摘要： Embodiments of the present systems and methods may provide techniques to predict the success or failure of a drug used for disease treatment. For example, a method of determining drug efficacy may include, for a plurality of patients, generating a directed acyclic graph from health related information of each patient comprising nodes representing a medical event of the patient, at least one first edge connecting the first node to an additional node, each additional edge connecting nodes representing two consecutive medical events, the edge having a weight based on a time difference between the two consecutive medical events, capturing a plurality of features from each directed acyclic graph, generating a binary graph classification model on captured features of each directed acyclic graph, determining a probability that a drug or treatment will be effective using the binary graph classification model, and determining a drug to be prescribed to a patient based on the determined probability.
-
公开(公告)号：US20230355136A1
公开(公告)日：2023-11-09
申请号：US18159847
申请日：2023-01-26
IPC分类号： A61B5/11 , A61B5/00 , G06F40/205
CPC分类号： A61B5/112 , A61B5/7267 , A61B5/742 , A61B5/7275 , G06F40/205 , A61B5/4842 , A61B2562/0247 , A61B2562/0219
摘要： A gait analysis system, which includes a neural network with a recurrent neural network layer and a fully connected layer, that receives sensor data indicative of an individual's gait and outputs an assessment regarding the individual's health. The neural network is trained using training data indicative of abnormal gaits and normal gaits. To analyze the training data and the sensor data, the recurrent neural network layer parses each piece of data into a series of windows and analyzes each window in series to generate a context vector characterizing each window and the previously analyzed windows. The fully connected layer, having been trained to differentiate between normal gaits and abnormal gaits based on context vectors characterizing the training data, is used to generate a final assessment characterizing the user gate as normal or abnormal using one or more of the context vectors characterizing the sensor data.
-
公开(公告)号：US11752215B2
公开(公告)日：2023-09-12
申请号：US17200136
申请日：2021-03-12
发明人： Siang-Yo Lin , Joseph R. Bertino , Chen-Yong Lin , Zoltan Szekely
IPC分类号： A61K47/68 , A61K47/65 , A61K47/60 , A61P35/00 , A61K31/40 , A61K31/4439 , C07K16/30 , C07K16/40 , A61K39/00
CPC分类号： A61K47/6871 , A61K31/40 , A61K31/4439 , A61K47/60 , A61K47/65 , A61K47/6803 , A61K47/6809 , A61K47/6811 , A61P35/00 , C07K16/30 , C07K16/40 , A61K2039/505 , C07K2317/73
摘要： The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.
-
公开(公告)号：US11728042B2
公开(公告)日：2023-08-15
申请号：US17406598
申请日：2021-08-19
发明人： Howard Federoff , Ophir Frieder
摘要： A triage system that determines whether a user is likely to have contracted a disease based on sensor data received from a user device (e.g., a smartphone or activity tracker). Each symptom is identified by comparing sensor data to a predetermined baseline and comparing the difference to a predetermined symptom threshold. Because direct measurement of symptoms using the sensors available to the user may not be feasible or sufficiently accurate, the triage system also uses surrogates the identify certain symptoms. For example, a fever may be identified using heart data, a cough or shortness of breath may be identified by analyzing recorded sound, fatigue may be identified by analyzing the movement of the user device, and loss of smell or taste may be identified by recording sound and using speech detection algorithms to identify phrases in the recorded sound indicative of loss of smell or taste.
-
公开(公告)号：US11696922B2
公开(公告)日：2023-07-11
申请号：US17555285
申请日：2021-12-17
申请人： Georgetown University , The United States of America, as represented by the Secretary, Department of Health & Human Services
发明人： Jill P. Smith , Stephan Stern , Abdullah Mahmud
IPC分类号： C07H21/02 , A61K31/7088 , C12N15/115 , A61K47/10 , A61K47/18 , A61K9/107 , A61K9/51 , C12N15/11 , A61K47/60 , A61K47/64 , A61K47/69 , A61K31/713 , C12N15/113 , A61P35/00 , A61K9/127 , B82Y5/00
CPC分类号： A61K31/7088 , A61K9/1075 , A61K9/127 , A61K9/5146 , A61K31/713 , A61K47/10 , A61K47/183 , A61K47/60 , A61K47/6455 , A61K47/6935 , A61P35/00 , B82Y5/00 , C12N15/111 , C12N15/113 , C12N15/115 , C12N2310/14 , C12N2310/16 , C12N2310/351 , C12N2320/30 , C12N2320/32
摘要： A construct, or a pharmaceutically acceptable salt thereof, comprising:
(a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized;
(b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and
(c) a siRNA complexed with the poly(L-lysine) of the polymer moiety,
wherein the construct is neutralized.-
公开(公告)号：US20230201223A1
公开(公告)日：2023-06-29
申请号：US18082973
申请日：2022-12-16
CPC分类号： A61K31/575 , A61K47/542 , A61K47/54 , A61P9/14 , A61K9/0019 , A61K47/02 , A61K47/10
摘要： Compositions comprising bile acids or their salts and methods of use thereof for the treatment of residual lesions of vascular anomalies.
-
公开(公告)号：US11688386B2
公开(公告)日：2023-06-27
申请号：US16643824
申请日：2018-08-31
CPC分类号： G10L15/02 , G06F3/016 , G10L21/16 , G10L2021/065
摘要： A method for training vibrotactile speech perception in the absence of auditory speech includes selecting a first word, generating a first control signal configured to cause at least one vibrotactile transducer to vibrate against a person's body with a first vibration pattern based on the first word, sampling a second word spoken by the person, generating a second control signal configured to cause at least one vibrotactile transducer to vibrate against the person's body with a second vibration pattern based on the sampled second word, and presenting a comparison between the first word and the second word to the person. An array of vibrotactile transducers can be in contact with the person's body. A method for improving auditory and/or visual speech perception in adverse listening conditions or for hearing-impaired individuals can also include sampling a speech signal, extracting a speech envelope, and generating a control signal configured to cause a vibrotactile transducer to vibrate again a person's body with an intensity that varies over time based on the speech envelope.
-
公开(公告)号：US11681965B2
公开(公告)日：2023-06-20
申请号：US16663547
申请日：2019-10-25
发明人： David Hartley , Ophir Frieder
IPC分类号： G06Q10/0635 , G06F16/215 , G06F21/60 , G06F21/62 , G06F21/00
CPC分类号： G06Q10/0635 , G06F16/215 , G06F21/00 , G06F21/602 , G06F21/6218 , G06F21/6254 , G06F2212/7205 , G06F2221/2143 , G06Q2220/10
摘要： A specialized computing environment that includes hardware and data security features to enable competitive organizations to co-analyze proprietary data without revealing the underlying proprietary data to unauthorized users. Proprietary data are stored in volatile memory, which may be automatically erased according to pre-stored criteria. The analysis is performed automatically by a processing unit without human intervention. Analytical results are sanitized (e.g., using data masking) to prevent the analytical result from being tracible to any particular data source. Sanitized analytical results are output without outputting the underlying proprietary data (except to users authorized to validate analytical results). The computing environment is enclosed within a secure enclosure (e.g., a steel box with a lock), does not include any peripheral devices outside the secure enclosure, does not communicate wirelessly, and does not have hardware ports accessible from outside the secure enclosure (except, in some embodiments, a wired connection for a web server).
-
-
-
-
-
-
-
-
-
搜索结果
496 条记录 (耗时 0.032 秒)
